Scarica l'app Stockscreener
9.30
2.31%
-0.22
Precedente Chiudi:
$9.52
Aprire:
$9.67
Volume 24 ore:
236.40K
Relative Volume:
2.00
Capitalizzazione di mercato:
$134.09M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-1.8343
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
-7.92%
1M Prestazione:
-3.63%
6M Prestazione:
-22.24%
1 anno Prestazione:
-45.87%
Intervallo 1D:
$9.27
$9.7863
Intervallo di 1 settimana:
$9.27
$10.07
Portata 52W:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Confronta ANIK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.30 | 137.29M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy |
| 2024-11-01 | Reiterato | Barrington Research | Outperform |
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Ripresa | Stephens | Equal-Weight |
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Iniziato | Stephens | Overweight |
| 2021-07-16 | Iniziato | UBS | Neutral |
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Iniziato | BWS Financial | Sell |
| 2019-09-24 | Reiterato | Barrington Research | Outperform |
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Reiterato | Barrington Research | Outperform |
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
How Anika Therapeutics Inc. (AKP) stock reacts to Fed tighteningMarket Volume Report & Smart Money Movement Alerts - newser.com
Can Anika Therapeutics Inc. (AKP) stock deliver consistent EPS growthJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Will Anika Therapeutics Inc. (AKP) stock hit analyst forecastsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Will Anika Therapeutics Inc. stock benefit from sector rotationWeekly Investment Report & Fast Gain Stock Tips - newser.com
How Anika Therapeutics Inc. stock responds to policy changesPortfolio Performance Summary & Risk Controlled Swing Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy on weakness - newser.com
How Anika Therapeutics Inc. (AKP) stock reacts to fiscal policies2025 Earnings Impact & Technical Entry and Exit Tips - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.2025 Retail Activity & AI Driven Price Forecasts - newser.com
How strong is Anika Therapeutics Inc. stock balance sheet2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
Is Anika Therapeutics Inc. stock attractive after correctionJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flowsEarnings Performance Report & Real-Time Stock Entry Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy before new product rolloutIPO Watch & Daily Profit Maximizing Tips - newser.com
Why Anika Therapeutics Inc. (AKP) stock stays resilient2025 Market Outlook & Reliable Breakout Forecasts - newser.com
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 Volatility Report & AI Powered Trade Plan Recommendations - newser.com
Will Anika Therapeutics Inc. stock reach all time highs in 20252025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock resilient in recession scenariosPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Is Anika Therapeutics Inc. stock undervalued vs historical averages2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
6.17%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):